GenSight raises EUR 40M in Euronext IPO

Gene therapy company GenSight Biologics S.A. (Euronext:SIGHT) raised EUR 40 million ($44.1 million) through the sale of 5 million shares at EUR 8 in an IPO on Euronext Paris. The offering valued the company at about EUR 148.9 million ($164.2 million). Oddo & Cie and Gilbert Dupont are underwriters.

In April, GenSight withdrew a proposed NASDAQ listing, citing market conditions. The company had filed in 2015 to raise up to $100 million. It priced Wednesday's offering near the bottom of its target range of EUR 7.80-EUR 9.20. ...